(A) Expression of FGFR1 and FGFR2 in wild-type rat chondrosarcoma (RCS) cells, RCS cells null for FGFR1–4, and RCS cells expressing only endogenous FGFR1 (RCSFgfr1). Actin serves as a loading …
Original files for the western blots in Figure 1A.
PDF containing Figure 1A and original western blots.
Original files for the western blots in Figure 1B.
PDF containing Figure 1B and original western blots.
Data plotted in Figure 1B.
Data plotted in Figure 1C.
(A) Brightness distributions shown on the linear scale. Brightness scales with the oligomer size. Linker for activation of T-cells (LAT) (gray) is a monomer control, TrkA+130 nM nerve growth factor …
Fluorescence intensity fluctuations (FIF) brightness value distributions.
(A) Sample western blots for Y653/4 FGFR1 phosphorylation and FRS2 phosphorylation in response to FGF4, FGF8, and FGF9. (B) An example blot used for data scaling, where samples with maximum …
Original files for the western blots in Figure 3A and B.
PDF containing Figure 3A and B and original western blots.
pY653/654 phosphorylation dose-response curves.
Y766 phosphorylation dose-response curves.
pPLCγ phosphorylation dose-response curves.
pFRS2 phosphorylation dose-response curves.
Fibroblast growth factor receptor (FGFR) downregulation dose-response curves.
(A) Phosphorylation time course of Y653/654 at high ligand concentration (130 nM). (B) Phosphorylation time course of Y653/654 at low ligand concentration (2.6 nM). (C) Phosphorylation time course …
All kinetics data plotted in Figure 4.
(A) FGFR1 concentration in the plasma membrane of HEK 293T cells at t=2 min following ligand addition for FGF8, FGF9, and no ligand control. (B) HEK 293T cell viability after ligand exposure and 6 …
FGFR1 membrane concentration, cell viability, and apoptosis data plotted in Figure 5A, B, and C.
Original files for the western blots in Figure 5D.
PDF containing Figure 5D and original western blots.
Collagen amounts, used to generate the dose-response curves for collagen type 2 loss in Figure 5E.
Cell counts, used to generate the dose-response curves for growth arrest in Figure 5F.
Shown are results for three different biologically independent samples in the absence of ligand, three samples that have been treated with FGF8 for 2 min, and three samples that have been treated …
Original files for the western blots in Figure 5—figure supplement 1.
PDF containing Figure 5—figure supplement 1 and original western blots.
(A and B) Förster resonance energy transfer (FRET) data for ECTM-FGFR1-YFP and ECTM-FGFR1-mCherry in the presence of saturating FGF4 (orange), FGF8 (green), or FGF9 (blue) concentrations. (A) …
FGF4 Förster resonance energy transfer (FRET) data.
FGF8 Förster resonance energy transfer (FRET) data.
FGF9 Förster resonance energy transfer (FRET) data.
EC50 is the potency of the ligand, and Etop is the efficacy (see Equation 1).
pY653/4 | PLCγ | ||||
---|---|---|---|---|---|
EC50, M | Etop | EC50, M | Etop | ||
FGF4 | 4.77E-10±0.42E-10 | 0.95±0.03 | FGF4 | 7.98E-11±2.15E-11 | 0.80±0.04 |
FGF8 | 1.04E-8±0.23E-8 | 1.11±0.07 | FGF8 | 1.05E-9±0.23E-9 | 0.99±0.03 |
FGF9 | 2.09E-9±0.31E-9 | 0.70±0.02 | FGF9 | 2.05E-10±0.40E-10 | 0.62±0.02 |
pY766 | pFRS2 | ||||
EC50, M | Etop | EC50, M | Etop | ||
FGF4 | 5.84E-10±1.26E-10 | 0.76±0.05 | FGF4 | 3.42E-10±0.70E-10 | 0.94±0.06 |
FGF8 | 1.42E-8±0.25E-8 | 1.16±0.07 | FGF8 | 1.62E-9±0.29E-9 | 0.98±0.03 |
FGF9 | 1.94E-9±0.71E-9 | 0.56±0.05 | FGF9 | 1.65E-9±0.15E-9 | 0.52±0.01 |
FGFR1 Downregulation | Growth arrest | ||||
EC50, M | Etop | EC50, M | Etop | ||
FGF4 | 7.34E-10±4.54E-10 | 0.27±0.04 | FGF4 | 2.59E-12±1.1E-13 | 0.99±0.00 |
FGF8 | 1.39E-8±0.39E-8 | 0.63±0.05 | FGF8 | 1.60E-9±2.3E-10 | 1.14±0.04 |
FGF9 | 6.80E-9±2.08E-9 | 0.42±0.02 | FGF9 | 5.89E-11±8.5E-12 | 0.95±0.00 |
Collagen type 2 loss | |||||
EC50, M | Etop | ||||
FGF4 | 1.24E-11±2.79E-12 | 1.02±0.01 | |||
FGF8 | 8.51E-11±2.86E-11 | 0.77±0.03 | |||
FGF9 | 5.67E-11±2.89E-11 | 0.86±0.06 |
Gray shading indicates statistical significance between either FGF4 or FGF9 and the reference ligand FGF8 (see Supplementary file 4 for p-values).
β | ||
---|---|---|
4v8 | 9v8 | |
pY653/4 vs pY766 | –0.07±0.16 | 0.05±0.15 |
pY653/4 vs PLCγ | –0.24±0.18 | 0.01±0.14 |
pY653/4 vs pFRS2 | –0.61±0.16 | –0.78±0.12 |
pY766 vs pPLCγ | –0.18±0.19 | –0.04±0.17 |
pY766 vs pFRS2 | –0.54±0.17 | –0.83±0.16 |
pPLCγ vs pFRS2 | –0.37±0.20 | –0.79±0.13 |
pY653/4 vs downregulation | –0.36±0.26 | –0.36±0.16 |
pY766 vs downregulation | –0.29±0.27 | –0.41±0.19 |
pPLCγ vs downregulation | –0.12±0.28 | –0.37±0.16 |
pFRS2 vs downregulation | 0.25±0.27 | 0.42±0.15 |
Collagen loss vs growth arrest | –1.77±0.20 | –1.13±0.18 |
Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
---|---|---|---|---|
Antibody | Fgfr1 (rabbit monoclonal) | Cell Signaling | 9740 | (1:1000) |
Antibody | Fgfr2 (rabbit polyclonal) | Santa Cruz | sc122 | (1:1000) |
Antibody | Collagen 2 (rabbit polyclonal) | Cedarlane | CL50241AP | (1:1000) |
Antibody | Actin (mouse monoclonal) | Cell Signaling | 3700 | (1:1000) |
Antibody | Vinculin (rabbit monoclonal) | Cell Signaling | 13901 | (1:1000) |
Antibody | pERK (rabbit polyclonal) | Cell Signaling | 9101 | (1:1000) |
Antibody | Anti-Y653/654 (rabbit polyclonal) | Cell Signaling | 3471S | (1:1000) |
Antibody | Anti-pY766 FGFR1 (rabbit monoclonal) | Cell Signaling | 2544S | (1:1000) |
Antibody | Anti-pFRS2 (rabbit monoclonal) | Cell Signaling | 3861S | (1:1000) |
Antibody | Anti-pPLCγ (rabbit polyclonal) | Cell Signaling | 2821S | (1:1000) |
Antibody | Anti-PLCγ (rabbit polyclonal) | Cell Signaling | 2822S | (1:1000) |
Antibody | Anti-V5 (mouse monocolonal) | Invitrogen | 46-0705 | (1:1000) |
Antibody (secondary) | Anti-rabbit | Promega | W4011 | (1:10,000) |
Antibody (secondary) | Anti-mouse | Millipore Sigma | A6782 | (1:10,000) |
Cell line (Homo sapiens) | HEK 293T FGFR1 | This paper | Stable cell line developed and maintained by Hristova lab, identity authenticated by SRT profiling, negative for mycoplasma | |
Cell line (Rattus norvegicus) | RCS WT | PMID:749928 | A gift from Benoit de Crombrugghe | |
Cell line (Rattus norvegicus) | RCS Fgfr1-4 null | PMID:33952673 | ||
Cell line (Rattus norvegicus) | RCSFgfr1 | This paper | Progenitors: Fgfr3/4 KO RCS cells from Carmine Settembre, identity authenticated by SRT profiling, negative for mycoplasma | |
Chemical compound, drug | 2× Laemmli Buffer | Bio-Rad | 1610737 | |
Chemical compound, drug | Tris/Gly/SDS running buffer | Bio-Rad | 1610732 | |
Chemical compound, drug | Transfer buffer | Bio-Rad | 1610734 | |
Chemical compound, drug | Fugene HD | Promega | E2311 | |
Commercial assay or kit | Bio-Rad Mini-Protean TGX precast gels | Bio-Rad | 4561026 | |
Commercial assay or kit | PVDF membranes | Bio-Rad | 1620177 | |
Commercial assay or kit | West Femto Supersignal | Thermo Fisher Scientific | 1706435 | |
Commercial assay or kit | Bio-Rad Magic Red Caspase 3-7 kit | Bio-Rad | ICT 935 | |
Commercial assay or kit | MTT Cell Proliferation Assay Kit | Cell BioLabs | CBS-252 | |
Other | Iblot 2 Gel Transfer Device | Thermo Fisher Scientific | IB21001 | Equipment for transfer |
Gene (Rattus norvegicus) | Fgfr1 | Ensembl | Ensembl:ENSRNOG00000016050 | |
Peptide, recombinant protein | FGF4 | R&D Systems | 235-F4-025 | |
Peptide, recombinant protein | FGF8 | R&D Systems | 423-F8-025 | |
Peptide, recombinant Protein | FGF9 | R&D Systems | 273-F9-025 | |
Recombinant DNA reagent | FGFR1-ECTM-eYFP (plasmid) | PMID:26725515 | YFP-Dr M. Betenbaugh, FGFR1 in pRK5- Dr M Mohammadi, into pcDNA3.1 vector | |
Recombinant DNA reagent | FGFR1-ECTM-mCherry (plasmid) | PMID:26725515 | pRSET-mCherry- Dr R.Tsien, FGFR1 in pRK5- Dr M Mohammadi, into pcDNA3.1 vector | |
Recombinant DNA reagent | pKrox(MapERK)d1EGFP | This paper | Addgene plasmid #214912 | Progenitors: pKrox24(MapErk)DsRed (PMID:28199182), pTR01F (PMID:24376882), d1EGFP (PMID:16508309), PCR of mEgr1 3’UTR |
Software | FIF software | PMID:31110281 | ||
Software | Mathematica | Wolfram | 13 | |
Software | Prism | GraphPad | 9.2.0 |
Best-fit Gaussian parameters for the different log(brightness) distributions.
Calculated Z values from the Gaussian fit parameters in Supplementary file 1.
β’4, β’8, and β’9 values calculated for each response using Equation 4.
Comparison of β’4, β’8, and β’9 values from Supplementary file 3.
Summary of results shown in Figure 5A–C.